Clinical Trial Update: A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating a heterologous HIV vaccine regimen (Ad26.Mos4.HIV with adjuvanted clade C gp140 and mosaic gp140) to prevent HIV-1 infection; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Ad26.Mos4.HIV vaccine (adenovirus serotype 26 mosaic4 HIV vaccine) (Adenovirus serotype 26 mosaic4 HIV vaccine)
• Adjuvanted clade C gp140 vaccine (Adjuvanted clade C gp140 vaccine)
• Mosaic gp140 vaccine (Mosaic gp140 envelope glycoprotein vaccine)

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Healthy | Phase 3 | Status: COMPLETED | Results posted: 2024-07-31